Lenvatinib Synthon (Lenvatinib)

Lenvatinib blocks multiple receptor tyrosine kinases such as VEGFR1‑3, FGFR1‑4, PDGFRα, RET and KIT. This inhibition reduces angiogenesis and tumor cell proliferation, thereby slowing cancer growth and spread.

The specific dose and dosing schedule are determined by the prescribing physician based on the patient’s condition, weight, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions exactly.

Lenvatinib is classified as pregnancy category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and breastfeeding is not recommended because the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lenvatinib and sorafenib are oral tyrosine kinase inhibitors, but lenvatinib targets a broader spectrum of receptors, including FGFRs, which may offer greater efficacy in certain cancers such as differentiated thyroid cancer. Safety profiles differ, with lenvatinib more frequently causing hypertension, while sorafenib is associated with hand‑foot skin reactions.

Lenvatinib should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Lenvatinib is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically instructed.

Serious risks include severe hypertension, hepatic failure, arterial thromboembolic events, gastrointestinal perforation or fistula formation, and life‑threatening bleeding. Patients should be monitored closely for signs of these events and report any sudden symptoms to their healthcare provider.

Lenvatinib is contraindicated in patients with known hypersensitivity to the drug, in pregnant women, and in individuals with uncontrolled hypertension or severe hepatic impairment. Caution is also advised for patients with recent major surgery or active gastrointestinal ulcers.